Switzerland: Novartis to acquire Gyroscope Therapeutics for up to US$1.5bn

Swiss multinational pharmaceutical corporation, Novartis, has entered into a definitive agreement to acquire all the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics for up to US$1.5bn. The acquisition adds an investigational, one-time gene therapy (GT005) currently in Phase 2 for the treatment of people living with geographic atrophy (GA), an…

You must be a HMI Subscriber to view this content.

Subscribe Now »